Viridian Therapeutics (NASDAQ:VRDN) Stock Price Target Raised at Wedbush

Viridian Therapeutics (NASDAQ:VRDN) had its price objective boosted by equities researchers at Wedbush from $41.00 to $42.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush‘s price objective points to a potential upside of 44.53% from the stock’s previous close.

Several other research analysts also recently commented on the company. Truist Financial boosted their target price on Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Weiss Ratings upgraded shares of Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 14th. HC Wainwright upped their price objective on shares of Viridian Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Royal Bank Of Canada upped their price objective on shares of Viridian Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 22nd. Finally, Needham & Company LLC increased their price objective on shares of Viridian Therapeutics from $34.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Viridian Therapeutics Price Performance

Shares of VRDN stock opened at $29.06 on Thursday. The company has a quick ratio of 16.95, a current ratio of 16.95 and a debt-to-equity ratio of 0.43. Viridian Therapeutics has a twelve month low of $13.18 and a twelve month high of $34.29. The company has a market cap of $3.29 billion, a P/E ratio of -8.62 and a beta of 1.07. The business has a fifty day simple moving average of $21.80 and a 200 day simple moving average of $21.85.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.21. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%. The business had revenue of $25.75 million for the quarter, compared to analyst estimates of $4.72 million. On average, sell-side analysts forecast that Viridian Therapeutics will post -4.07 EPS for the current fiscal year.

Insiders Place Their Bets

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total value of $348,194.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Viridian Therapeutics

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its holdings in shares of Viridian Therapeutics by 0.3% during the first quarter. Bank of New York Mellon Corp now owns 216,525 shares of the company’s stock worth $4,235,000 after purchasing an additional 659 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Viridian Therapeutics by 6.6% in the third quarter. ProShare Advisors LLC now owns 12,609 shares of the company’s stock valued at $260,000 after buying an additional 784 shares during the period. 71 West Capital Partners raised its holdings in Viridian Therapeutics by 4.1% in the 3rd quarter. 71 West Capital Partners now owns 22,282 shares of the company’s stock valued at $459,000 after buying an additional 882 shares during the last quarter. Pictet Asset Management Holding SA raised its holdings in Viridian Therapeutics by 13.5% in the 3rd quarter. Pictet Asset Management Holding SA now owns 12,741 shares of the company’s stock valued at $262,000 after buying an additional 1,516 shares during the last quarter. Finally, KBC Group NV acquired a new stake in Viridian Therapeutics during the 1st quarter worth approximately $34,000.

Key Headlines Impacting Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Viridian reported a Q3 loss of $0.81 per share, narrower than analysts’ expected loss of $1.01–$1.02. Revenue of $25.75 million also exceeded the roughly $4.72 million consensus estimate. The EPS loss was nevertheless wider than the $0.34 loss a year earlier. Viridian Q3 results
• Positive Sentiment: Management signaled it is targeting a biologics license application for elegrobart in Q1 2027 and expects Lumvoa’s launch to reach broad coverage within six to nine months—milestones that could strengthen the commercial and pipeline outlook. Elegrobart and Lumvoa outlook
• Positive Sentiment: Needham raised its price target to $38 from $34 and maintained a Buy rating, reflecting a more optimistic analyst view of VRDN’s prospects. Needham price target update
• Negative Sentiment: A Yahoo Finance commentary said VRDN looks overvalued even with its new launch, highlighting valuation as a potential concern after the stock’s strong performance. Valuation commentary

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.